Document is current

Any future updates will be listed below

FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms

Crossref DOI link: https://doi.org/10.1186/1756-0500-7-260

Published Online: 2014-04-23

Published Print: 2014-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark